{
  "@type": "dcat:Dataset",
  "accessLevel": "public",
  "accrualPeriodicity": "R/P1Y",
  "bureauCode": [
    "009:10"
  ],
  "contactPoint": {
    "@type": "vcard:Contact",
    "fn": "Division of Drug Information",
    "hasEmail": "mailto:druginfo@fda.hhs.gov"
  },
  "description": "Fiasp is a fast-acting insulin aspart injection used to control blood sugar levels in people with diabetes. Manufactured by Novo Nordisk, it's available as a subcutaneous solution in pens and cartridges, with strengths like 100 units/mL. It helps manage hyperglycemia when used with diet and exercise. This information was generated using AI and is provided for informational and research purposes only.",
  "distribution": [
    {
      "@type": "dcat:Distribution",
      "description": "\n        Access the FDA dataset for Insulin aspart injection — ANDA 208751 submitted by Mylan Institutional LLC\n    ",
      "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208751",
      "mediaType": "text/html",
      "title": "Insulin aspart injection"
    }
  ],
  "identifier": "ANDA208751",
  "issued": "2016-09-16",
  "keyword": [
    "drug",
    "drug-information",
    "drug-safety",
    "medications",
    "public-health"
  ],
  "landingPage": "https://www.fda.gov/drugs",
  "license": "https://open.fda.gov/license",
  "modified": "2025-03-17",
  "programCode": [
    "009:002"
  ],
  "publisher": {
    "@type": "org:Organization",
    "name": "U.S. Food and Drug Administration"
  },
  "theme": [
    "FDA"
  ],
  "title": "Insulin aspart injection"
}